Matthew Davis, M.D.

Medical Director
Rochester Clinical Research

Disclosure(s): No financial relationships to disclose

Poster(s):

• (P-596) Immunobridging Demonstrating Effectiveness of the Bivalent Respiratory Syncytial Virus (RSV) Prefusion F Subunit Vaccine in Adults 18-59 Years of Age at High Risk of Severe RSV Disease in a Phase 3 Trial: The C3671023 MONeT Study Results
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-601) Safety and Immunogenicity of a Respiratory Syncytial Virus and Human Metapneumovirus Virus-like Particle Protein Subunit Combination Vaccine in 60–85-Year-Old Adults: Interim Results from a Phase 2a Clinical Trial
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT